The use of diacylglycerol kinase inhibitors for elucidating the roles of protein kinase C.
de Chaffoy de Courcelles
D
D
Department of Biochemistry, Janssen Research Foundation, Beerse, Belgium.
D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000201:enzymology; D019852:Diacylglycerol Kinase; D004075:Diglycerides / Q000096:biosynthesis / Q000502:physiology; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D009504:Neutrophils / Q000187:drug effects / Q000201:enzymology; D010770:Phosphotransferases / Q000037:antagonists & inhibitors*; D010880:Piperidines / Q000494:pharmacology*; D011493:Protein Kinase C / Q000502:physiology*; D011744:Pyrimidinones / Q000494:pharmacology*; D011799:Quinazolines / Q000494:pharmacology*; D052999:Quinazolinones; D011817:Rabbits; D011956:Receptors, Cell Surface / Q000187:drug effects; D015290:Second Messenger Systems / Q000187:drug effects*; D013844:Thiazoles / Q000494:pharmacology*
C011439:1,2-diacylglycerol; D004075:Diglycerides; D010880:Piperidines; D011744:Pyrimidinones; D011799:Quinazolines; D052999:Quinazolinones; D011956:Receptors, Cell Surface; D013844:Thiazoles; C058544:R 59949; C047505:R 59022; D010770:Phosphotransferases; D019852:Diacylglycerol Kinase; D011493:Protein Kinase C